Assignee
OCTAPHARMA AG
CH·38 granted patents·24 pending applications·192 citations·filing 1992–2025
Top patents by PatentIndex Score
62 records- 0191US7553938B2Method of providing a purified, virus safe antibody preparationOCTAPHARMA AG·Filed 2005·Granted Jun 30, 2009·56 cites·26 claims
- 0287US8769841B2Lyophilisation targeting defined residual moisture by limited desorption energy levelsOCTAPHARMA AG·Filed 2012·Granted Jul 8, 2014·17 cites·9 claims
- 0379US10640548B2Method for inactivation/removal of coagulation factors by precipitationOCTAPHARMA AG·Filed 2017·Granted May 5, 2020·3 cites·13 claims
- 0479US6518406B1Method for purification of proteinsOCTAPHARMA AG·Filed 2000·Granted Feb 11, 2003·4 cites·11 claims
- 0578US11191833B2High concentration immunoglobulin composition for pharmaceutical applicationOCTAPHARMA AG·Filed 2017·Granted Dec 7, 2021·2 cites·13 claims
- 0678US7166709B2Haemostatically active preparation containing vWF and method for the production thereofOCTAPHARMA AG·Filed 2001·Granted Jan 23, 2007·12 cites·7 claims
- 0778US5328694AStable injectable solution of factor VIIIOCTAPHARMA AG·Filed 1992·Granted Jul 12, 1994·51 cites·14 claims
- 0875US7985846B2Hemostatically active vWF-containing preparation and process for the preparation thereofOCTAPHARMA AG·Filed 2007·Granted Jul 26, 2011·2 cites·8 claims
- 0973US6893856B2Process for preparing virus-inactivated factors 1X and X by membrane chromatographyOCTAPHARMA AG·Filed 2002·Granted May 17, 2005·3 cites·17 claims
- 1071US10214575B2Process for the purification of a growth factor proteinOCTAPHARMA AG·Filed 2016·Granted Feb 26, 2019·1 cites·17 claims
- 1170US11383002B2Plasma-based films and methods for making and using the sameOCTAPHARMA AG·Filed 2020·Granted Jul 12, 2022·0 cites·15 claims
- 1269US2024002841A1Means and methods for modifying multiple allelesOCTAPHARMA AG·Filed 2023·Application pending·0 cites
- 1369US2023374501A1Means and methods for modifying multiple allelesOCTAPHARMA AG·Filed 2023·Application pending·0 cites
- 1465US11738069B2Polypeptides modulating SIGLEC dependent immune responsesOCTAPHARMA AG·Filed 2021·Granted Aug 29, 2023·0 cites·25 claims
- 1564US12233126B2High concentration immunoglobulin composition for pharmaceutical applicationOCTAPHARMA AG·Filed 2021·Granted Feb 25, 2025·0 cites·16 claims
- 1663US2024415945A1C1-esterase inhibitor preparationOCTAPHARMA AG·Filed 2024·Application pending·0 cites
- 1762US11383001B2Plasma-based films and methods for making and using the sameOCTAPHARMA AG·Filed 2017·Granted Jul 12, 2022·0 cites·31 claims
- 1862US9943600B2Stabilizing agent for pharmaceutical proteinsOCTAPHARMA AG·Filed 2014·Granted Apr 17, 2018·1 cites·11 claims
- 1962US2025177601A1Biodegradable, non-porous medical device and methods for making and using the sameOCTAPHARMA AG·Filed 2023·Application pending·0 cites
- 2059US12171808B2Glycosylated VWF fusion proteins with improved pharmacokineticsOCTAPHARMA AG·Filed 2017·Granted Dec 24, 2024·0 cites·28 claims
- 2159US2009092678A1Universally applicable blood plasmaOCTAPHARMA AG·Filed 2008·Application pending·0 cites
- 2256US12274738B2FX activation process and its use in the preparation of a FXa compositionOCTAPHARMA AG·Filed 2019·Granted Apr 15, 2025·0 cites·20 claims
- 2356US10626431B2Method for improved isolation of recombinantly produced proteinsOCTAPHARMA AG·Filed 2016·Granted Apr 21, 2020·0 cites·12 claims
- 2456US9796986B2Serum-free stable transfection and production of recombinant human proteins in human cell linesOCTAPHARMA AG·Filed 2016·Granted Oct 24, 2017·0 cites·20 claims
- 2555US11713458B2Means and methods for modifying multiple allelesOCTAPHARMA AG·Filed 2017·Granted Aug 1, 2023·0 cites·11 claims
- 2655US2025144655A1Mold for applying a liquid onto a plasma-based or cryoprecipitate-based film and method for coating a plasma-based or cryoprecipitate-based filmOCTAPHARMA AG·Filed 2023·Application pending·0 cites
- 2754US12083171B2C1-esterase inhibitor preparationOCTAPHARMA AG·Filed 2018·Granted Sep 10, 2024·0 cites·26 claims
- 2854US2007014806A1Universally applicable blood plasmaOCTAPHARMA AG·Filed 2006·Application pending·0 cites
- 2953US7700732B2Prekallikrein depleted plasma derived albumin fractionOCTAPHARMA AG·Filed 2003·Granted Apr 20, 2010·1 cites·3 claims
- 3053US2025222079A1Fx activation process and its use in the preparation of a fxa compositionOCTAPHARMA AG·Filed 2025·Application pending·0 cites
- 3152US11401300B2Process for production of fibrinogen and fibrinogen produced therebyOCTAPHARMA AG·Filed 2018·Granted Aug 2, 2022·0 cites·7 claims
- 3252US10112972B2Process for production of fibrinogen and fibrinogen produced therebyOCTAPHARMA AG·Filed 2013·Granted Oct 30, 2018·0 cites·25 claims
- 3352US2015190478A1New protecting compositions for recombinantly produced factor viiOCTAPHARMA AG·Filed 2014·Application pending·0 cites
- 3451US2019358301A1Protecting compositions for recombinantly produced factor viiiOCTAPHARMA AG·Filed 2018·Application pending·0 cites
- 3550US11013789B2Polypeptides modulating SIGLEC dependent immune responsesOCTAPHARMA AG·Filed 2017·Granted May 25, 2021·0 cites·27 claims
- 3650US2008172902A1Lyophilisation targeting defined residual moisture by limited desorption energy levelsOCTAPHARMA AG·Filed 2007·Application pending·0 cites
- 3750US2019030169A1Stabilizing agent for pharmaceutical proteinsOCTAPHARMA AG·Filed 2018·Application pending·0 cites
- 3850US2022305089A1Stabilizing buffer for factor viii and vwfOCTAPHARMA AG·Filed 2020·Application pending·0 cites
- 3949US6777541B2Protein purification IIOCTAPHARMA AG·Filed 2001·Granted Aug 17, 2004·0 cites·11 claims
- 4049US2015152498A1Assay and method for predicting therapeutic efficacy of immunoglobulin therapy in individual patients with relapsing remitting multiple sclerosis (rr-ms)OCTAPHARMA AG·Filed 2013·Application pending·0 cites
- 4149US2015031621A1Method for purification of complement factor hOCTAPHARMA AG·Filed 2014·Application pending·0 cites
- 4248US2016152661A1Process for isolation and purification of a target protein free of prion protein (prpsc)OCTAPHARMA AG·Filed 2015·Application pending·0 cites
- 4347US10098956B2Stabilizing agent for pharmaceutical proteinsOCTAPHARMA AG·Filed 2016·Granted Oct 16, 2018·0 cites·10 claims
- 4447US9938318B2Process for production of fibrinogenOCTAPHARMA AG·Filed 2016·Granted Apr 10, 2018·0 cites·11 claims
- 4546US5919909AProcess for the preparation of factor IX from biological sourcesOCTAPHARMA AG·Filed 1996·Granted Jul 6, 1999·10 cites·13 claims
- 4645US2017189494A1Protecting compositions for recombinantly produced factor viiiOCTAPHARMA AG·Filed 2017·Application pending·0 cites
- 4744US10251940B2Preparation comprising factor VIII and Von Willebrand factor peptidesOCTAPHARMA AG·Filed 2015·Granted Apr 9, 2019·0 cites·19 claims
- 4844US2015250879A1Test for hemolytic potential of pharmaceutical products and formulations for risk minimizationOCTAPHARMA AG·Filed 2013·Application pending·0 cites
- 4944US2006194300A1Process for preparing an alpha-1-antitrypsin solutionOCTAPHARMA AG·Filed 2004·Application pending·0 cites
- 5043US2002182195A1Universally applicable blood plasmaOCTAPHARMA AG·Filed 2002·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →